A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Phase of Trial: Phase IV
Latest Information Update: 28 Oct 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms START
- Sponsors Novartis; Novartis Pharmaceuticals
- 28 Oct 2017 Final results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
- 24 Dec 2016 Status changed from recruiting to completed.
- 11 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.